Published • loading... • Updated
R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first patient randomized in the global Phase 2b trial of AP306 conducted in partnership with Alebund in the US and China Study builds on positive Phase 2a […] The post R1 Therapeutics announces commencement of global Phase 2b trial of …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium